The T. Rowe Price Health Sciences strategy is among the better options available given its strong investment resources, research depth, and framework.
T. Rowe Price Health Sciences PRHSX
- NAV / 1-Day Return 99.78 / −0.24 %
- Total Assets 15.3 Bil
-
Adj. Expense Ratio
- Expense Ratio 0.800%
- Distribution Fee Level Below Average
- Share Class Type No Load
- Category Health
- Investment Style Large Growth
- Min. Initial Investment 2,500
- Status Open
- TTM Yield 0.00
- Turnover 48%
USD | NAV as of Sep 27, 2024 | 1-Day Return as of Sep 27, 2024, 10:20 PM GMT+0
Morningstar’s Analysis PRHSX
Will PRHSX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 53.8
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
Eli Lilly and Co | 12.05 | 1.8 Bil | Healthcare |
Aggregate Miscellaneous Equity | 8.31 | 1.2 Bil | — |
UnitedHealth Group Inc | 6.45 | 962.4 Mil | Healthcare |
Intuitive Surgical Inc | 4.77 | 711.4 Mil | Healthcare |
Thermo Fisher Scientific Inc | 4.42 | 659.6 Mil | Healthcare |
Merck & Co Inc | 3.95 | 589.1 Mil | Healthcare |
Elevance Health Inc | 3.73 | 556.2 Mil | Healthcare |
Stryker Corp | 3.56 | 531.3 Mil | Healthcare |
Danaher Corp | 3.42 | 510.3 Mil | Healthcare |
Regeneron Pharmaceuticals Inc | 3.16 | 471.5 Mil | Healthcare |